Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer

RECOMMENDED

Genitourinary Cancer

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncol.

Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C

Genitourinary Cancer

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

Lancet Oncol.

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM; Radium-223 International Early Access Program Investigators

doi: 10.1016/

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Clin Genitourin Cancer.

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S

doi: 10.1016/j.clgc.2017.08.020.

Genitourinary Cancer

Olaparib for Metastatic Castration-Resistant Prostate Cancer

N Engl J Med.

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M

doi: 10.1056/NEJMoa1911440.

Genitourinary Cancer

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

Eur Urol.

Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM

doi: 10.1016/j.eururo.2020.04.061.

Genitourinary Cancer

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data

Lancet Oncol.

Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC; Prostate Cancer Challenge DREAM Community.

Genitourinary CancerRadio-Oncology

Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group

Eur Urol Oncol.

O'Sullivan JM, Carles J, Cathomas R, Gomez-Iturriaga A, Heinrich D, Kramer G, Ost P, van Oort I, Tombal B

doi: 10.1016/j.euo.2019.02.007.

Genitourinary Cancer

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Eur J Nucl Med Mol Imaging.

Du Y, Carrio I, De Vincentis G, Fanti S, Ilhan H, Mommsen C, Nitzsche E, Sundram F, Vogel W, Oyen W, Lewington V

doi: 10.1007/s00259-017-3756-7.

Genitourinary Cancer

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

Expert Rev Clin Pharmacol.

Vogelzang NJ

doi: 10.1080/

Related content

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data

Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases